Breast cancer is a highly heterogeneous malignancy among women worldwide. Traditional prognostic models relying solely on clinicopathological features offer limited predictive accuracy and lack ...

"RethinkBH and Raintree are combining our strengths to deliver tools that meet the real-world needs of multidisciplinary therapy practices," said Rethink CEO Ben Semmes. "We want to make life easier ...

Extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) have become a critical global public health challenge due to their high resistance to β-lactam antibiotics and association with severe ...

Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a ...

ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB)Estimate 55% of ...

Trial Superiority Testing -- Statistical analysis plan allows for hierarchical testing of superiority after non-inferiority ...

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) ("WeightWatchers,” "WW,” or the "Company”) today announced its results for the third quarter of fiscal 2025 ended ...

Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to pr ...

Cynata Therapeutics Limited ( OTCPK:CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation November 5, 2025 8:30 PM EST ...

Q3 2025 Earnings Call Transcript November 3, 2025 BioNTech SE misses on earnings expectations. Reported EPS is $-0.14 EPS, ...

Thank you, operator. Good morning and good afternoon, everybody, and thank you for joining BioNTech's Third Quarter 2025 Earnings Call. As a reminder, the slides we'll use during the call and the ...